BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32020370)

  • 1. High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson's disease cohort.
    Fazio P; Ferreira D; Svenningsson P; Halldin C; Farde L; Westman E; Varrone A
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2407-2416. PubMed ID: 32020370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease.
    Wilson H; Giordano B; Turkheimer FE; Chaudhuri KR; Politis M
    Neuroimage Clin; 2018; 18():630-637. PubMed ID: 29845011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.
    Chou KL; Dayalu P; Koeppe RA; Gilman S; Spears CC; Albin RL; Kotagal V
    Mov Disord; 2022 Nov; 37(11):2301-2307. PubMed ID: 36102173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.
    Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ
    Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.
    Qamhawi Z; Towey D; Shah B; Pagano G; Seibyl J; Marek K; Borghammer P; Brooks DJ; Pavese N
    Brain; 2015 Oct; 138(Pt 10):2964-73. PubMed ID: 26209314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: An ultra-high resolution PET-MRI study.
    Kim JH; Son YD; Kim JH; Choi EJ; Lee SY; Joo YH; Kim YB; Cho ZH
    Brain Res; 2015 Dec; 1629():63-71. PubMed ID: 26459992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter.
    Strecker K; Wegner F; Hesse S; Becker GA; Patt M; Meyer PM; Lobsien D; Schwarz J; Sabri O
    J Neurol; 2011 Jan; 258(1):19-26. PubMed ID: 20644949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.
    Wilson H; Dervenoulas G; Pagano G; Koros C; Yousaf T; Picillo M; Polychronis S; Simitsi A; Giordano B; Chappell Z; Corcoran B; Stamelou M; Gunn RN; Pellecchia MT; Rabiner EA; Barone P; Stefanis L; Politis M
    Lancet Neurol; 2019 Aug; 18(8):748-759. PubMed ID: 31229470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal
    Pasquini J; Ceravolo R; Brooks DJ; Bonuccelli U; Pavese N
    Parkinsonism Relat Disord; 2020 Aug; 77():170-175. PubMed ID: 30981664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT.
    Schain M; Tóth M; Cselényi Z; Arakawa R; Halldin C; Farde L; Varrone A
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):228-37. PubMed ID: 23076621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies.
    Pagano G; Niccolini F; Fusar-Poli P; Politis M
    Ann Neurol; 2017 Feb; 81(2):171-180. PubMed ID: 28019672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrastriatal
    Nicastro N; Garibotto V; Burkhard PR
    BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonergic mediated body mass index changes in Parkinson's disease.
    Politis M; Loane C; Wu K; Brooks DJ; Piccini P
    Neurobiol Dis; 2011 Sep; 43(3):609-15. PubMed ID: 21624463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data.
    Fazio P; Schain M; Varnäs K; Halldin C; Farde L; Varrone A
    Neuroimage; 2016 Jun; 133():313-320. PubMed ID: 26994829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.
    Guttman M; Boileau I; Warsh J; Saint-Cyr JA; Ginovart N; McCluskey T; Houle S; Wilson A; Mundo E; Rusjan P; Meyer J; Kish SJ
    Eur J Neurol; 2007 May; 14(5):523-8. PubMed ID: 17437611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin transporter availability in thalamic subregions in schizophrenia: a study using 7.0-T MRI with [(11)C]DASB high-resolution PET.
    Kim JH; Son YD; Kim JH; Choi EJ; Lee SY; Lee JE; Cho ZH; Kim YB
    Psychiatry Res; 2015 Jan; 231(1):50-7. PubMed ID: 25465315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.